HÄMOGLOBINZUSAMMENSETZUNGEN

European patent · EP2440239 · Deleted

Register entry

Publication number
EP2440239
Application number
EP10727289
Kind
European patent with effect for Switzerland and Liechtenstein
Status
Deleted
Specification
Granted
Filed
Jun 9, 2010
Published
Apr 18, 2012
Granted
Sep 13, 2017
Deleted
Jun 30, 2020
Reason
Annual fee unpaid
IPC classes
A61K 9/08 (2006.01)
A61K 38/42 (2006.01)
A61K 47/18 (2017.01)
Priority
US 185547 P 09.06.2009
PCT application
PCT/US2010/038046 09.06.2010
PCT publication
WO2010/144629 16.12.2010
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jan 20, 2021

    Deleted, fee unpaid

    Published in Swissreg on 20.01.2021

  2. Nov 21, 2017

    Agent entered

    Representative
    MICHELI & CIE SA, 122, Rue de Genève, Case postale 61, 1226 Thônex

    Published in Swissreg on 21.11.2017

  3. Sep 13, 2017

    Granted

    Published in Swissreg on 13.09.2017

Parties

Holder

Prolong Pharmaceuticals, LLC

300 Corporate Court Suite B, South Plainfield, NJ 07080, US

Agent

MICHELI & CIE SA

122, Rue de Genève Case postale 61, 1226 Thônex

Inventor

ABUCHOWSKI, Abraham

Califon NJ 07830, US

SLOSHBERG, Steven

Union NJ 07083, US

O'HARE, Keith

East Windsor NJ 08520, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.